公开(公告)号：US20100169987A1

公开(公告)日：2010-07-01

申请号：US12478957

申请日：2009-06-05

申请人： Laurent Lecanu ,  Vassilios Papadopulos ,  Janet Greeson

发明人： Laurent Lecanu ,  Vassilios Papadopulos ,  Janet Greeson

IPC分类号： G01N33/48 ,  A01K67/027

CPC分类号： A01K67/027 ,  A01K2227/105 ,  A01K2267/0312 ,  A61K49/0008

摘要： The present invention relates to the development of a pharmacological non-human animal model that associates memory loss to histopathological features found in the brain of a subject having Alzheimer's Disease. In one embodiment, a four-week continuous infusion of a Fe2+, Aβ42 and buthionine sulfoximine (FAB) solution in the left ventricle of young adult Long-Evans rats induced memory impairment accompanied by increased hyperphosphorylated Tau protein levels in cerebrospinal fluid. Brains from treated animals displayed neuritic plaques, tangles, neuronal loss, astrogliosis and microgliosis in hippocampus and cortex. The present invention may be utilized in evaluating preventive, therapeutic and diagnostic means for neurologic diseases.

摘要翻译： 本发明涉及药物非人动物模型的开发，其将记忆丧失与在具有阿尔茨海默病的受试者脑中发现的组织病理学特征相关联。 在一个实施方案中，在年轻成年的Long-Evans大鼠的左心室中连续输注一次Fe2 +，Aβ42和丁硫氨酸磺酰亚胺（FAB）四周，引起记忆障碍，伴随脑脊液中过度磷酸化的Tau蛋白水平升高。 治疗动物的大脑显示出海马和皮层神经炎斑块，缠结，神经元损失，星形胶质细胞增生和微胶质细胞增生。 本发明可用于评估神经疾病的预防，治疗和诊断手段。